Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUTI-16 Safety and Immunogenicity in HIV
NCT01144026Phase 2Completed
- Sponsor
- Thymon
- Start
- Sep 2010
- Primary completion
- Apr 2011
- Modality
- Cyclic Peptides, Vaccines & Immunotherapeutics, Peptide Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of TUTI-16 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Thymon. Primary endpoint: Anti-Tat Antibody Titer at 5 weeks. Started Sep 2010; status: completed.
02
Drugs
TUTI-16
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01144026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144026.